Tumor
Markers
Tumor markers are substances characteristically associated with malignant neoplasms. They may be produced by tumor cells themselves, abnormally expressed by these cells, or generated by the host in response to tumor stimulation. These markers reflect the occurrence and progression of cancer and are widely used to support diagnosis, prognosis, and treatment monitoring. KSB tumor marker assays provide valuable clinical diagnostic information to support patient care.
Tumor markers are biologically derived substances that are characteristically associated with malignant tumors and the complex molecular processes underlying cancer development. These substances may be produced directly by tumor cells, expressed at abnormally high levels due to genetic or regulatory alterations within malignant tissues, or generated by the host organism as part of an immune, inflammatory, or metabolic response to tumor presence and progression. In clinical oncology, tumor markers encompass a broad range of biomolecules, including proteins, glycoproteins, enzymes, hormones, antigens, receptors, and nucleic acid fragments, all of which may reflect abnormal cellular proliferation and tumor biology.
The presence and concentration of tumor markers often correlate with clinically relevant parameters such as tumor burden, disease stage, histological type, metastatic spread, and therapeutic response. As a result, tumor markers are widely applied in oncology practice as supportive tools for early detection strategies, prognostic assessment, treatment monitoring, and post-therapy surveillance. While most tumor markers do not exhibit sufficient specificity or sensitivity to serve as standalone diagnostic criteria, their longitudinal measurement provides valuable insight into disease dynamics and patient response to treatment interventions such as surgery, chemotherapy, radiotherapy, targeted therapies, and immunotherapies.
Tumor markers can be detected in a range of biological samples, including blood, serum, plasma, urine, stool, and other body fluids, depending on the clinical relevance and intended diagnostic application of each marker. Their measurement is most commonly performed using immunological techniques, which provide the sensitivity and specificity required for reliable clinical interpretation. Among these, immunochromatographic lateral flow assays are widely used due to their simplicity, rapid turnaround time, and suitability for POCT. These assays enable fast and convenient detection of tumor-associated biomarkers, supporting screening, diagnostic, and treatment monitoring in both laboratory and decentralized healthcare settings.
In particular, immunochromatographic lateral flow assays represent a rapid and user-friendly platform for tumor marker detection at the point of care. KSB tumor marker assays enable qualitative (FOB) or quantitative (all the other assays) analysis within minutes, supporting timely clinical decision-making in hospitals, laboratories, and decentralized healthcare settings. By combining antibody-based recognition with membrane-driven capillary flow, lateral flow technology allows for efficient and cost-effective screening and monitoring of tumor-associated biomarkers. As such, tumor marker testing remains an essential component of modern in-vitro diagnostics, supporting improved patient management and more responsive oncology care pathways.
Explore
Your
Options
Shenzhen Kang Sheng Bao
Biotechnology Co., Ltd.
Second Floor, Block 3, Anda
Electronic Industrial Park,
Fuhai, Bao’an District,
518103 Shenzhen,
Guangdong Province, PRC
+86 0755 27417763
info@ksbbiotech.com
© 2026 Shenzhen Kang Sheng Bao Bio-Technology Co., Ltd. All Rights Reserved